Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Validation

Migration, Crosslink

📖

Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Validation

active

wiki page Created: 2026-04-02T07:20:09 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-experiments-mhtt-clearance-mechanis

📖 Wiki Page

experiment876 wordssynced 2026-04-02

Hypothesis

flowchart TD experiments_mhtt_clearance_mec["Mutant Huntingtin mHTT Clearance Mechanisms The"] experiments_mhtt_clearance_mec["Hypothesis"] experiments_mhtt_clearance_mec -->|"related to"| experiments_mhtt_clearance_mec style experiments_mhtt_clearance_mec fill:#81c784,stroke:#333,color:#000 experiments_mhtt_clearance_mec["Different"] experiments_mhtt_clearance_mec -->|"related to"| experiments_mhtt_clearance_mec style experiments_mhtt_clearance_mec fill:#81c784,stroke:#333,color:#000 experiments_mhtt_clearance_mec["species"] experiments_mhtt_clearance_mec -->|"related to"| experiments_mhtt_clearance_mec style experiments_mhtt_clearance_mec fill:#81c784,stroke:#333,color:#000 experiments_mhtt_clearance_mec["full-length"] experiments_mhtt_clearance_mec -->|"related to"| experiments_mhtt_clearance_mec style experiments_mhtt_clearance_mec fill:#81c784,stroke:#333,color:#000 style experiments_mhtt_clearance_mec fill:#4fc3f7,stroke:#333,color:#000

Different [mHTT](/genes/htt) species (full-length, N-terminal fragments, oligomers, aggregates) have distinct pathogenicities, and optimal [therapeutic targeting](/therapeutics/) requires understanding which species drive [neurodegeneration](/diseases/) and how to achieve sustained protein lowering without compensatory upregulation. This connects to the broader [protein aggregation](/mechanisms/mutant-huntingtin-aggregation) literature and [autophagy](/mechanisms/autophagy-lysosome-pathway)-based clearance strategies.

Gap Addressed

...

Hypothesis

Mermaid diagram (expand to render)

Different [mHTT](/genes/htt) species (full-length, N-terminal fragments, oligomers, aggregates) have distinct pathogenicities, and optimal [therapeutic targeting](/therapeutics/) requires understanding which species drive [neurodegeneration](/diseases/) and how to achieve sustained protein lowering without compensatory upregulation. This connects to the broader [protein aggregation](/mechanisms/mutant-huntingtin-aggregation) literature and [autophagy](/mechanisms/autophagy-lysosome-pathway)-based clearance strategies.

Gap Addressed

HD Knowledge Gap #1 (Score: 31): [mHTT](/genes/htt) clearance mechanisms — addresses which [mHTT](/genes/htt) species are most toxic, optimal timing of intervention, and how to achieve sustained protein lowering without compensatory upregulation. This gap intersects with [Huntington's disease](/diseases/huntingtons) therapeutics development and [gene silencing](/therapeutics/antisense-oligonucleotides) approaches.

Key Mechanisms and Targets

This experiment connects to core [Huntington's disease](/diseases/huntingtons) pathways:

Pathogenic mHTT Species

Full-length mHTT: Contains the polyglutamine tract, interacts with [transcription factors](/mechanisms/htt-transcriptional-dysregulation-pathway), [cargo proteins](/mechanisms/htt-transcriptional-dysregulation-pathway), [mitochondria](/mechanisms/mitochondrial-dysfunction)
N-terminal fragments: Generated by proteolytic cleavage ([caspase-6](/genes/casp6), calpains), more aggregative, propagate between [neurons](/cell-types/striatal-neurons)
Oligomers: Intermediate toxic species — [synaptic dysfunction](/mechanisms/synaptic-dysfunction-pathway), [mitochondrial](/mechanisms/mitochondrial-dysfunction) toxicity
Aggregates/ inclusions: Historically thought protective (sink hypothesis), now recognized as mixed

Clearance Mechanisms

[Autophagy](/mechanisms/autophagy-lysosome-pathway): [Macroautophagy](/mechanisms/autophagy) and [chaperone-mediated autophagy](/mechanisms/chaperone-mediated-autophagy) can clear [mHTT](/genes/htt)
[Ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system): Early-stage clearance; [proteasome](/mechanisms/ubiquitin-proteasome-system) impairment in [HD](/diseases/huntingtons)
[Protein quality control](/mechanisms/ubiquitin-proteasome-system): [HSP70](/proteins/hsp70-protein), [HSP40](/genes/dnaJB6) co-chaperones
[Lysosomal degradation](/mechanisms/lysosomal-dysfunction): [mHTT](/genes/htt) clearance via [lysosomal](/mechanisms/lysosomal-dysfunction) pathways

Therapeutic Targets

[ASOs](/therapeutics/antisense-oligonucleotides): [HTT-targeting ASOs](/therapeutics/antisense-oligonucleotides) (e.g., [tominersen](/therapeutics/tominersen)) reduce [mHTT](/genes/htt) expression
[RNAi](/therapeutics/rna-interference-huntingtons): [siRNA](/therapeutics/rna-interference-huntingtons), [shRNA](/therapeutics/rna-interference-huntingtons) approaches
[Small molecule degraders](/therapeutics/proteolysis-targeting-chimeras-neurodegeneration): [PROTACs](/therapeutics/proteolysis-targeting-chimeras-neurodegeneration) recruiting [E3 ligases](/mechanisms/e3-ubiquitin-ligase-system)
[Aggregation inhibitors](/therapeutics/aggregation-inhibitors-huntingtons): Prevent toxic oligomer formation
[Autophagy enhancers](/therapeutics/mTOR-independent-autophagy-inducers): [rapamycin](/therapeutics/rapamycin-tauopathy), [carbamazepine](/therapeutics/carbamazepine-autophagy) — [mTOR-independent](/therapeutics/mTOR-independent-autophagy-inducers) inducers

[Alzheimer's disease](/diseases/alzheimers-disease): [APP](/genes/app) processing parallels [HTT](/genes/htt) cleavage; [BACE inhibitors](/therapeutics/bace-inhibitors-alzheimers) lessons applicable
[Parkinson's disease](/diseases/parkinsons-disease): [Alpha-synuclein](/proteins/alpha-synuclein) aggregation and clearance mechanisms parallel [mHTT](/genes/htt)
[Spinocerebellar ataxias](/diseases/spinocerebellar-ataxia-type-7): Polyglutamine expansions share mechanism with [HD](/diseases/huntingtons)
[Transcription dysregulation](/mechanisms/htt-transcriptional-dysregulation-pathway): [mHTT](/genes/htt) sequesters [transcription factors](/mechanisms/htt-transcriptional-dysregulation-pathway) including [REST](/entities/rest), [p53](/mechanisms/p53-parkinson-disease)

Experimental Design

Aim 1: Define Toxic mHTT Species Hierarchy

Approach: Characterize the relative toxicity of different mHTT species using multi-modal detection and functional assays

Model System:

In vitro: Recombinant mHTT proteins (full-length, N-terminal fragments, oligomers)
Cellular: iPSC-derived striatal neurons from HD patients (various CAG lengths)
Animal: BACHD and HTTdh knock-in mouse models

Readouts:

ThT/fluorescent aggregation kinetics for each species
Seed amplification assay (SAA) to detect distinct conformers
Live-cell imaging of mHTT aggregation in neurons
Correlation with cell death markers (caspase activation, viability)
Synaptic function assessment (electrophysiology, dendritic spine analysis)

Key Questions:

Which species (full-length, fragments, oligomers) correlates best with neurodegeneration?
Do different conformers have distinct spreading properties?
What post-translational modifications (phosphorylation, truncation) modify toxicity?

Aim 2: Optimize mHTT Lowering Strategies

Approach: Compare ASO, RNAi, CRISPR, and small molecule approaches for efficiency and sustainability

Interventions to Compare:

ASO-mediated splicing modulation (HTT-ASO, tominersen approach)

RNAi-mediated knockdown (shRNA, siRNA targeting HTT mRNA)

CRISPR-based allele-specific editing (discriminate mutant from wild-type)

Autophagy enhancement (small molecules, TFEB activation)

Proteolysis targeting chimeras (PROTACs) (mHTT-specific degraders)

Model System:

iPSC-derived neurons from HD patients with different CAG expansions
Primary neurons from HD mouse models
Humanized mouse models with inducible mutant HTT expression

Readouts- HTT protein levels (ELISA, Western blot) — total and mutant-specific

mRNA levels (qPCR, RNA-seq)
Behavioral rescue in animal models
Off-target effects (wild-type HTT lowering, pathway dysregulation)
Compensatory mechanisms (autophagy induction, translational upregulation)

Aim 3: Timing and Window of Intervention

Approach: Determine the optimal disease stage for mHTT lowering

Design:

Premanifest HD cohort enrollment (CAG > 40, pre-motor symptoms)
Early manifest HD (Disease Burden Score < 250)
Moderate HD (UHDRS TFC 7-13)
Late HD (TFC < 7)

Biomarkers:

Neurofilament light chain (NfL) in CSF/plasma
PET imaging of mHTT aggregates
Structural MRI (striatal volume)
Clinical endpoints (UHDRS, TFC)

Outcomes:

Optimal intervention window based on biomarker trajectory
Correlation between baseline biomarker levels and treatment response

Aim 4: Biomarker Development for Treatment Response

Approach: Identify biomarkers that predict and monitor treatment response

Candidate Biomarkers:

Plasma/CSF NfL (neurodegeneration marker)
Phospho-tau isoforms (disease progression)
Neurogranin (synaptic integrity)
YKL-40 (neuroinflammation)
mHTT-specific SAA from CSF

Validation:

Longitudinal samples from ongoing ASO trials
Correlation with clinical endpoints

Expected Outcomes

Toxicity hierarchy — Rank mHTT species by relative contribution to neurodegeneration

Optimal lowering strategy — Determine which approach achieves sustained mHTT reduction with minimal off-target effects

Intervention timing — Define the optimal window for mHTT lowering based on biomarker trajectories

Response biomarkers — Identify biomarkers that predict treatment response and enable patient stratification

Feasibility and Cost

| Component | Estimated Cost | Timeline |
|-----------|----------------|----------|
| Aim 1: Species characterization | $1.2M | 18 months |
| Aim 2: Strategy comparison | $2.5M | 24 months |
| Aim 3: Timing study (human) | $3.0M | 36 months |
| Aim 4: Biomarker validation | $1.5M | 24 months |
| Total | $8.2M | 48 months |

Risk Assessment

Technical risk: Medium — iPSC and animal models are established; species characterization requires validated assays
Regulatory risk: Low — ASO approach validated by tominersen; clear regulatory pathway
Ethical considerations: Premanifest enrollment requires careful informed consent and genetic counseling

References

[Kieburtz et al., Tominersen trial outcomes (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)

[Tabrizi et al., Huntington disease biomarkers (2023)](https://pubmed.ncbi.nlm.nih.gov/37252945/)

[Miller et al., mHTT lowering strategies (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)

[Caron et al., Somatic CAG expansion in HD (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)

[Mandel et al., AAV delivery to CNS (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)

📖 View canonical wiki page →

Related Entities

experiments-mhtt-clearance-mechanisms-hd

▸Metadataorigin_type: v1_polymorphic_backfill

slug	experiments-mhtt-clearance-mechanisms-hd
kg_node_id	None
entity_type	experiment
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-47522b61403c
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'experiments-mhtt-clearance-mechanisms-hd'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

66

Outgoing

74

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Validation

Hypothesis

Gap Addressed

Hypothesis

Gap Addressed

Key Mechanisms and Targets

Pathogenic mHTT Species

Clearance Mechanisms

Therapeutic Targets

Experimental Design

Aim 1: Define Toxic mHTT Species Hierarchy

Aim 2: Optimize mHTT Lowering Strategies

Aim 3: Timing and Window of Intervention

Aim 4: Biomarker Development for Treatment Response

Expected Outcomes

Feasibility and Cost

Risk Assessment

References

💬 Discussion

📗 Cite This Artifact

Mutant Huntingtin (mHTT) Clearance Mechanisms — Therapeutic Target Validation

Hypothesis

Gap Addressed

Hypothesis

Gap Addressed

Key Mechanisms and Targets

Pathogenic mHTT Species

Clearance Mechanisms

Therapeutic Targets

Related Diseases and Mechanisms

Experimental Design

Aim 1: Define Toxic mHTT Species Hierarchy

Aim 2: Optimize mHTT Lowering Strategies

Aim 3: Timing and Window of Intervention

Aim 4: Biomarker Development for Treatment Response

Expected Outcomes

Feasibility and Cost

Risk Assessment

References

💬 Discussion